Your browser is no longer supported. Please, upgrade your browser.
Settings
RPRX [NASD]
Royalty Pharma plc
Index- P/E24.67 EPS (ttm)1.49 Insider Own0.20% Shs Outstand383.99M Perf Week-4.65%
Market Cap22.34B Forward P/E11.96 EPS next Y3.07 Insider Trans-69.67% Shs Float176.77M Perf Month-11.64%
Income564.30M PEG3.08 EPS next Q0.69 Inst Own62.80% Short Float5.75% Perf Quarter-12.13%
Sales2.19B P/S10.18 EPS this Y-66.60% Inst Trans4.66% Short Ratio4.62 Perf Half Y-23.63%
Book/sh12.71 P/B2.89 EPS next Y11.55% ROA3.50% Target Price52.71 Perf Year-14.95%
Cash/sh3.90 P/C9.43 EPS next 5Y8.00% ROE12.30% 52W Range34.80 - 53.23 Perf YTD-26.59%
Dividend0.68 P/FCF- EPS past 5Y- ROI14.70% 52W High-30.98% Beta-
Dividend %1.85% Quick Ratio9.40 Sales past 5Y- Gross Margin- 52W Low5.57% ATR1.06
Employees51 Current Ratio9.40 Sales Q/Q14.40% Oper. Margin65.30% RSI (14)28.29 Volatility2.84% 2.56%
OptionableYes Debt/Eq0.00 EPS Q/Q-3.00% Profit Margin25.70% Rel Volume0.93 Prev Close37.68
ShortableYes LT Debt/Eq1.19 EarningsAug 11 BMO Payout31.60% Avg Volume2.20M Price36.74
Recom2.40 SMA20-8.38% SMA50-12.13% SMA200-15.89% Volume2,038,486 Change-2.49%
Jul-30-21Initiated Tigress Financial Buy $50
Nov-09-20Upgrade UBS Neutral → Buy $52 → $51
Jul-14-20Initiated Evercore ISI In-line
Jul-13-20Initiated UBS Neutral $52
Jul-13-20Initiated SunTrust Buy $56
Jul-13-20Initiated Morgan Stanley Equal-Weight $51
Jul-13-20Initiated JP Morgan Neutral $50
Jul-13-20Initiated Goldman Neutral $47
Jul-13-20Initiated Cowen Outperform $55
Jul-13-20Initiated Citigroup Neutral $50
Jul-13-20Initiated BofA Securities Buy $55
Jul-29-21 07:02AM  
Jul-19-21 09:00AM  
Jul-16-21 09:00AM  
Jul-15-21 04:54PM  
Jul-13-21 10:41AM  
Jul-05-21 05:30AM  
Jun-07-21 09:00AM  
Jun-02-21 07:40AM  
May-18-21 08:49AM  
May-11-21 08:00PM  
07:00AM  
05:45AM  
May-07-21 09:00AM  
Apr-21-21 04:15PM  
08:10AM  
Apr-15-21 09:00AM  
Apr-08-21 07:40AM  
07:30AM  
Apr-01-21 07:30AM  
Mar-30-21 08:00AM  
Mar-11-21 02:37PM  
Feb-17-21 12:30PM  
07:00AM  
05:45AM  
Feb-15-21 05:30AM  
Jan-29-21 11:35PM  
Jan-22-21 08:00AM  
Jan-19-21 08:30AM  
08:00AM  
Jan-08-21 08:05AM  
08:00AM  
Jan-07-21 04:15PM  
Dec-23-20 03:16PM  
Dec-22-20 08:30AM  
Dec-21-20 08:12AM  
Dec-17-20 04:29PM  
Dec-07-20 08:45AM  
08:40AM  
Dec-04-20 04:31PM  
Nov-16-20 03:39AM  
Nov-10-20 05:40PM  
Nov-02-20 07:30AM  
Oct-20-20 04:32PM  
Oct-19-20 09:00AM  
Oct-15-20 11:45PM  
09:15AM  
Oct-13-20 04:10PM  
Oct-02-20 07:00AM  
Sep-16-20 11:42AM  
Sep-02-20 04:25PM  
08:00AM  
Aug-25-20 08:14AM  
08:00AM  
Aug-19-20 09:00AM  
Aug-12-20 07:00AM  
Aug-07-20 09:40AM  
Aug-03-20 04:15PM  
Jul-20-20 04:15PM  
07:45AM  
Jul-17-20 12:00PM  
Jul-15-20 04:33PM  
Jul-13-20 10:16AM  
Jul-02-20 01:02PM  
Jul-01-20 01:48PM  
Jun-30-20 10:40AM  
Jun-27-20 07:13PM  
Jun-26-20 04:42PM  
Jun-25-20 07:01PM  
08:43AM  
Jun-22-20 06:10PM  
Jun-18-20 04:15PM  
12:37PM  
09:53AM  
Jun-17-20 09:55AM  
06:06AM  
Jun-16-20 06:21PM  
05:34PM  
04:21PM  
03:21PM  
12:14PM  
12:10PM  
09:32AM  
07:07AM  
Jun-15-20 11:29PM  
07:21PM  
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and 5 development-stage product candidates in various therapeutic areas, such as rare disease, oncology, neurology, infectious disease, cardiology, and diabetes. The company has royalties on various product, such as Cystic fibrosis franchise, including Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio; HIV franchise comprising Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza, and Biktarvy; Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas, and Nesina; Tysabri, Imbruvica, Xtandi, Promacta, Farxiga/Onglyza, Prevymis, Emgality, Crysvita, Erleada, IDHIFA, Trodelvy, Nurtec ODT, Tazverik, and Evrysdi; and other products, such as Bosulif, Cimzia, Conbriza/Fablyn/Viviant, Entyvio, Lexiscan, Mircera, Myozyme, Nesina, Priligy, and Soliqua, as well as Tecfidera, Letairis, Lyrica, Remicade, Humira, Prezista, Rotateq, and Thalomid. Royalty Pharma plc was founded in 1996 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lloyd George W.EVP, Investments & GCJul 26Sale39.7813,362531,532595,860Jul 27 05:29 PM
Reddoch James F.EVP, Research & InvestmentsJul 26Sale39.788,949355,9771,170,800Jul 27 05:25 PM
Reddoch James F.EVP, Research & InvestmentsJul 26Sale39.788,949355,9771,170,800Jul 27 05:23 PM
Reddoch James F.EVP, Research & InvestmentsJul 14Sale42.002841,179,749Jul 14 05:17 PM
Lloyd George W.EVP, Investments & GCJul 13Sale42.0123,049968,252600,773Jul 14 05:18 PM
Reddoch James F.EVP, Research & InvestmentsJul 13Sale42.0117,832749,0811,179,751Jul 14 05:17 PM
Reddoch James F.EVP, Research & InvestmentsJul 12Sale42.041004,2041,197,583Jul 14 05:17 PM
Lloyd George W.EVP, Investments & GCJul 12Sale42.041004,204806,430Jul 14 05:18 PM
Reddoch James F.EVP, Research & InvestmentsJul 08Sale42.0540,6551,709,3801,197,683Jul 08 07:37 PM
Lloyd George W.EVP, Investments & GCJul 08Sale42.0549,0592,062,789605,841Jul 08 07:36 PM
Lloyd George W.EVP, Investments & GCJul 07Sale42.012,900121,828614,233Jul 08 07:36 PM
Reddoch James F.EVP, Research & InvestmentsJul 07Sale42.012,19292,0871,238,338Jul 08 07:37 PM
Reddoch James F.EVP, Research & InvestmentsJul 06Sale42.4030,2701,283,5601,240,530Jul 08 07:37 PM
Lloyd George W.EVP, Investments & GCJul 06Sale42.4136,5301,549,145614,633Jul 08 07:36 PM
RIGGS RORY BDirectorJun 29Sale41.26481,00019,844,8463,451,258Jun 29 08:31 PM
RIGGS RORY BDirectorJun 28Sale42.11167,4487,051,2693,932,258Jun 29 08:31 PM
RIGGS RORY BDirectorJun 25Sale42.72666,46428,474,019933,910Jun 29 08:31 PM
Lloyd George W.EVP, Investments & GCJun 10Sale46.4970,0003,254,369240,000Jun 14 06:42 PM
Lloyd George W.EVP, Investments & GCJun 08Sale46.4870,0003,253,631250,000Jun 08 08:12 PM
Reddoch James F.EVP, Research & InvestmentsJun 08Sale46.4350,0002,321,5401,270,800Jun 08 08:12 PM
Reddoch James F.EVP, Research & InvestmentsJun 07Sale46.5950,0002,329,4191,320,800Jun 08 08:12 PM
Lloyd George W.EVP, Investments & GCJun 07Sale46.34122,5005,676,228260,000Jun 08 08:12 PM
Urist MarshallEVP & Co-Head of R&IJun 07Sale47.0216,568779,0590Jun 08 08:15 PM
Urist MarshallEVP & Co-Head of R&IJun 04Sale45.1316,566747,66216,568Jun 08 08:15 PM
Lloyd George W.EVP, Investments & GCJun 04Sale44.7860,0002,686,938280,000Jun 08 08:12 PM
Reddoch James F.EVP, Research & InvestmentsJun 04Sale44.60100,0004,459,7301,370,800Jun 08 08:12 PM
Urist MarshallEVP & Co-Head Research & Inv.Jun 02Sale41.5214,566604,85033,134Jun 04 06:52 PM
Reddoch James F.EVP, Research & InvestmentsJun 02Sale42.1350,0002,106,5601,470,800Jun 04 06:50 PM
Lloyd George W.EVP, Investments & GCApr 14Sale42.1369,8222,941,92050,000Apr 16 05:57 PM
Reddoch James F.EVP, Research & InvestmentsApr 14Sale42.1055,7142,345,593200,000Apr 16 05:56 PM
Reddoch James F.EVP, Research & InvestmentsApr 12Sale42.3235915,193255,714Apr 14 07:51 AM
Lloyd George W.EVP, Investments & GCApr 12Sale42.3244919,00263,924Apr 14 07:52 AM
Lloyd George W.EVP, Investments & GCMar 22Sale46.3254,7292,535,22664,013Mar 24 05:25 PM
Reddoch James F.EVP, Research & InvestmentsMar 22Sale46.3243,9272,034,519256,073Mar 24 05:25 PM
Coyne Terrance P.EVP & CFOMar 03Sale44.78100,0004,478,450200,000Mar 05 07:04 PM
Lloyd George W.EVP, Investments & GCMar 02Sale46.94125,0005,867,14875,000Mar 04 07:03 PM
Reddoch James F.EVP, Research & InvestmentsMar 02Sale46.92100,0004,692,158300,000Mar 04 07:02 PM
Coyne Terrance P.EVP & CFOMar 02Sale46.94100,0004,694,090300,000Mar 04 07:00 PM
Fernandez Henry ADirectorFeb 25Buy46.8325,7001,203,48025,700Feb 26 07:46 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerDec 18Sale44.02101,0504,448,22138,714,280Dec 18 02:36 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerDec 17Sale43.927,200,000316,224,00038,815,330Dec 18 02:36 PM
RIGGS RORY BDirectorOct 20Sale42.00463,20019,454,4000Oct 22 09:48 PM